Cancer patients can respond very differently to the same treatment, while current testing may not reliably identify the therapy most likely to work for each tumor.
R&D Focus
Clinical-stage oncology company that specializes in precision medicine for cancer patients
Innovative Solution
Scorpion Therapeutics is a clinical-stage oncology company specializing in precision medicine for cancer patients. It develops targeted small-molecule drugs to interact with validated cancer targets.
Investment Funding
Last Funding Stage
Series C
Total Funding Amount
420.M
Last Funding Amount
150.M
Last Funding Date
16-07-2024
Startup Stage
M&A
Lead Investors
Lightspeed Venture Partners, Wellington Management, OrbiMed, Fidelity, Vida Ventures
Revenue
$1M to $10M
People
Founders
Gaddy Getz
Gary Glick
Keith Flaherty
Liron Bar-Peled
About
Scorpion Therapeutics is a clinical-stage oncology company specializing in precision medicine for cancer patients. It develops targeted small-molecule drugs to interact with validated cancer targets. It aims to leverage its platform to advance a broad pipeline of wholly-owned, optimized compounds across molecules targeting validated oncogene targets, molecules for previously undruggable targets, and molecules for novel cancer targets.
Products
Product
STX-478 – an oral mutant-selective PI3Kα inhibitor in Phase 1/2 for breast cancer and other advanced solid tumors.
Star Product
STX-478 – the lead precision-oncology program acquired by Eli Lilly.
Demo Product or Complete Product?
Clinical-stage – Phase 1/2.
M&A and Collabs
Acquisitions
Eli Lilly agreed in January 2025 to acquire Scorpion’s STX-478 PI3Kα inhibitor program for up to $2.5 billion; remaining assets were to be placed in a new company.
Something missing or incorrect on this page? Help us enrich this information
